DEF 14A: CVRx, Inc. Announces Annual Stockholders Meeting to Elect Directors and Ratify Accounting Firm

CVRx, Inc. will hold its 2025 annual meeting of stockholders virtually on June 3, 2025, to elect two Class I directors and ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm.

Summary

• CVRx, Inc. is holding its 2025 annual meeting of stockholders on June 3, 2025, in a virtual format.
• Stockholders will vote to elect Kevin Ballinger and Mitch Hill as Class I directors for terms expiring in 2028.
• The meeting will also include a vote to ratify the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The record date for determining eligible voters is April 7, 2025.
• The Board of Directors recommends voting in favor of the director nominees and the ratification of Grant Thornton.
• As of April 7, 2025, there were 26,056,808 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, outlining the details of the upcoming annual meeting. The tone is professional and straightforward, with no significant positive or negative sentiment expressed. The board's recommendations are clear and supportive of the proposals.

Positives

• The Board is recommending experienced candidates for election as directors.
• The company is following good corporate governance practices by seeking stockholder ratification of the independent auditor appointment.
• The company provides multiple avenues for stockholders to vote, including online, telephone, and mail.
• The company is committed to transparency by providing access to proxy materials and a virtual meeting format.

Risks

• If stockholders fail to ratify the appointment of Grant Thornton, the Audit Committee will reconsider its selection, potentially leading to additional costs and disruption.
• The company's reliance on a virtual meeting format may present technical challenges for some stockholders.
• As an emerging growth company, CVRx is exempt from certain reporting requirements, which may limit the information available to investors.

Future Outlook

The document outlines the procedures and deadlines for stockholders to submit proposals for inclusion in the 2026 annual meeting proxy statement and to nominate directors or propose other business for consideration at the 2026 annual meeting.

Management Comments

• Jared Oasheim, Chief Financial Officer, signed the notice of the annual meeting.
• The Board believes that Mr. Ballinger's experience in the medical device industry, as an executive leader, and as a member of the boards of directors of multiple companies in the healthcare industry qualifies him to serve as a director on the Board.
• The Board believes that Mr. Hill's extensive finance and business experience, including in the medical device industry, and his expertise in public accounting qualify him to serve as a director on the Board.
• The Board believes that Mr. Hykes leadership of our company as our President and Chief Executive Officer, as well as his significant senior executive leadership experience in the healthcare technology industry, uniquely positions him to contribute to the Board.
• The Board believes that Mr. Slattery's extensive finance and business experience in the life sciences industry and his expertise in public accounting qualify him to serve as a director on the Board.
• The Board believes that Dr. Jain's experience as a venture capital investor and expertise in biomedical engineering qualify him to serve as a director on the Board.
• The Board believes that Mr. Nielsen's extensive management experience serving on the boards of directors of several medical technology companies qualifies him to serve as a director on the Board.
• The Board believes that Ms. Shadan's significant executive leadership experience in the healthcare technology industry qualifies her to serve as a director on the Board.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions regarding the company's leadership and financial oversight.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is consistent with industry practices for publicly traded companies of similar size and complexity.
• The use of Grant Thornton as the independent registered public accounting firm is a common practice, and the disclosure of fees paid for audit and related services aligns with SEC requirements.
• The virtual meeting format is increasingly common, offering convenience and cost savings while allowing for stockholder participation.
• The company's corporate governance guidelines and committee charters are in line with best practices for publicly traded companies.

Management Changes

Related Party Transactions

• The company has an Investors Rights Agreement with holders of convertible preferred stock and certain holders of common stock, including entities affiliated with some directors, granting them rights regarding the registration of their shares.

Stakeholder Impact

• Stockholders have the opportunity to vote on key decisions regarding the company's leadership and financial oversight.
• Employees are subject to a Code of Business Conduct and Ethics and an Insider Trading Policy.
• The company's performance and governance practices impact its reputation and relationships with customers, suppliers, and creditors.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will file a Form 8-K with the SEC to report the final voting results of the Annual Meeting.
• The Board and its committees will continue to oversee the company's operations and governance.

Key Dates

Keywords

annual meeting, proxy statement, directors, Grant Thornton, stockholders, election, ratification, corporate governance, voting